Approval of fidaxomicin tablets was based on 2 trials involving 564 patients with CDAD. In those trials, fidaxomicin was shown to have an efficacy and safety similar to those of vancomycin. The trials ...

Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option. In a meta-analysis ...

The relative efficacy of Optimer Pharma's investigational antibiotic, fidaxomicin, compared to standard-of-care vancomycin (marketed as Vancocin by drugmaker ViroPharma), remains unclear. Published ...

Am J Health Syst Pharm. 2012;69(11):933-943. Based on current clinical trials reporting fewer recurrences among patients treated with fidaxomicin in which the non-NAP1/BI/027 strains were isolated, ...

Learn everything you need to know about Fidaxomicin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge ...

Please provide your email address to receive an email when new articles are posted on . Fidaxomicin was the most rational fiscal strategy compared with vancomycin for Clostridium difficile-associated ...

Review the side-effects of Fidaxomicin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Optimer announced the combined data from its two Phase 3 trials of fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI). The two fidaxomicin clinical studies were multi ...

Please provide your email address to receive an email when new articles are posted on . Data from two phase 3 trials indicate that fidaxomicin is minimally absorbed in patients with Clostridium ...

Scientists have determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC 'urgent threat' ...